0001765581-23-000036.txt : 20230310 0001765581-23-000036.hdr.sgml : 20230310 20230310181038 ACCESSION NUMBER: 0001765581-23-000036 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230308 FILED AS OF DATE: 20230310 DATE AS OF CHANGE: 20230310 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sablich Kim CENTRAL INDEX KEY: 0001758790 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33500 FILM NUMBER: 23725132 MAIL ADDRESS: STREET 1: C/O MYOVANT SCIENCES INC. STREET 2: 2000 SIERRA POINT PARKWAY CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jazz Pharmaceuticals plc CENTRAL INDEX KEY: 0001232524 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981032470 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: FIFTH FLOOR, WATERLOO EXCHANGE STREET 2: WATERLOO ROAD CITY: DUBLIN STATE: L2 ZIP: 4 BUSINESS PHONE: 353-1-634-7800 MAIL ADDRESS: STREET 1: FIFTH FLOOR, WATERLOO EXCHANGE STREET 2: WATERLOO ROAD CITY: DUBLIN STATE: L2 ZIP: 4 FORMER COMPANY: FORMER CONFORMED NAME: JAZZ PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030513 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2023-03-08 0 0001232524 Jazz Pharmaceuticals plc JAZZ 0001758790 Sablich Kim 5TH FL, WATERLOO EXCHANGE WATERLOO RD DUBLIN 4 L2 IRELAND 0 1 0 0 EVP, GM of U.S., Commercial Ma Ordinary Shares 2023-03-08 4 S 0 1752 139.42 D 31821 D Ordinary Shares 2023-03-08 4 S 0 1261 140.19 D 30560 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $138.95 to $139.94. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $139.97 to $140.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. By: Adam Guttman, as attorney in fact For: Kimbely Sablich 2023-03-10